Your SlideShare is downloading. ×
EUPATI Launch Meeing: Anders Olauson
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

EUPATI Launch Meeing: Anders Olauson

784

Published on

EUPATI Launch Meeting, 27 March 2012, Copenhagen: Anders Olauson

EUPATI Launch Meeting, 27 March 2012, Copenhagen: Anders Olauson

Published in: Health & Medicine, Business
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
784
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. A paradigm shift in public understanding of medical R&DAnders Olauson, President European Patients’ Forum
  • 2. Unmet needs for most patientswith life-threatening diseases “Success stories” available only to small numbers of rare cancers, rare diseases, other life-threatening conditions, young and very old patients Patients need therapeutic innovation – urgently!Source: RareCare (2012)
  • 3. Patients need innovation --paradigm shift in drug developmentInnovation turns e.g. cancer,rare diseases upside down: Molecular targets/pathways New approaches Genome sequencing, needed Translational research  clinical trial design Personalized medicine  trial recruitment • Small trial populations  relationship • Biomarkers required between Need for post-marketing data researchers, Health Technology Assessment, regulators, industry, QoL, endpoints, comparators patients Healthcare budgets vs drug pricing
  • 4. Overcoming public scrutinyon research Lack of public confidence in research leads to • lack of trial recruitment (6-12% of cancer patients take part in research) • delayed generation of meaningful clinical data • slow progress or lack of research • bad image of research in population Objective information to the public & more transparency urgently needed
  • 5. Patients orgs: key role in buildingnew environment for drugdevelopment Patient organisations have unique insights in „real life“ and „real needs“ of patients: • Gap analysis in research priorities • Clinical trial design • Priority setting in healthcare budgets Driving force • Research policy Co-researcher Reviewer Training required to get expertise Advisor required to contribute to scientific projects Info provider Research subject Source: PatientPartner FP7 Project (2010)
  • 6. EUPATI: The paradigm shift ininvolving patients in medical R&D Great individual initiatives to train patient advocates - by patient organisations, academia, industry, healthcare professionals, Complemented by: The Patients’ Academy – a paradigm shift in collaborative efforts of all stakeholders to make drug development more effective in Europe Wishing you success!
  • 7. Get to know us! Web: www.patientsacademy.eu Twitter: @eupatients as well as:

×